24-h uric acid excretion and the risk of kidney stones.
paper
Cited
Public
Unavailable
- Authors
- Curhan, G C; Taylor, E N
- Year
- 2008
- Journal
- Kidney international
- PMID
- 18059457
- DOI
- 10.1038/sj.ki.5002708
There is uncertainty about the relation between 24-h urinary uric acid excretion and the risk of calcium oxalate nephrolithiasis. In addition, the risk associated with different levels of other urinary factors needs clarification. We performed a cross-sectional study of 24-h urine excretion and the risk of kidney stone formation in 3350 men and women, of whom 2237 had a history of nephrolithiasis. After adjusting for other urinary factors, urinary uric acid had a significant inverse association with stone formation in men, a marginal inverse association with risk in younger women, and no association in older women. The risk of stone formation in men and women significantly rose with increasing urine calcium and oxalate, and significantly decreased with increasing citrate and urine volume, with the change in risk beginning below the traditional normal thresholds. Other urinary factors were also associated with risk, but this varied by age and gender. Our study does not support the prevailing belief that higher urine uric acid excretion increases the risk for calcium oxalate stone formation. In addition, the current definitions of normal levels for urinary factors need to be re-evaluated.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. | 2010 | 20700436 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Calcium Phosphate Nephrolithiasis: A Comprehensive Review. | Tsai P et al. | β | 2026 | β |
| Kidney Stone Events and ESKD Incidence in Patients with Enteric Hyperoxaluria from Diverse Enteric Etiologies. | Tatton RW et al. | β | 2026 | β |
| Nephrolithiasis: A Paleolithic Perspective and Physiological Approach to Prevention. | Ganesan C et al. | β | 2026 | β |
| Where does endogenous oxalate come from? - a systematic review of endogenous sources of urinary oxalate. | Dick B et al. | β | 2026 | β |
| Calcium to magnesium ratio as a superior biomarker for nephrolithiasis detection in primary hyperparathyroidism. | YalΓ§Δ±n N et al. | β | 2025 | β |
| Citrate and calcium kidney stones. | Zomorodian A et al. | β | 2025 | β |
| Factors Influencing Oxalate Synthesis in Healthy Volunteers. | Fargue S et al. | β | 2025 | β |
| [Gender Disparities in Urolithiasis with a Special Focus on Oxalate Metabolism in the Liver]. | Herout R et al. | β | 2025 | β |
| Idiopathic Hypercalciuria: A Comprehensive Review of Clinical Insights and Management Strategies. | Meher D et al. | β | 2025 | β |
| Impact of body composition on vitamin D requirements in healthy adults with vitamin D deficiency. | Dai D et al. | β | 2025 | β |
| Improved 24-hour urine parameters associated with reduced symptomatic kidney stone recurrence. | Sui W et al. | β | 2025 | β |
| Inducing <i>Oxalobacter formigenes</i> Colonization Reduces Urinary Oxalate in Healthy Adults. | Fargue S et al. | β | 2025 | β |
| Kidney stone disease: risk factors, pathophysiology and management. | Bargagli M et al. | β | 2025 | β |
| Metabolic Differences in 24-Hour Urine Parameters Between Calcium Oxalate Monohydrate and Dihydrate Kidney Stones: A Clinical Study. | Gadzhiev N et al. | β | 2025 | β |
| OxDc-A0: an oral gastro-tolerant oxalate decarboxylase for treating secondary hyperoxaluria. | Liu HF et al. | β | 2025 | β |
| Re-defining the interpretation of 24-h urine studies for stone formers. | Sui W et al. | β | 2025 | β |
| Sex and Age Variation for Nephrolithiasis Risk Factors on 24-Hour Urine Metabolic Evaluation: A Real-World Single-center Retrospective Analysis. | Sultan MI et al. | β | 2025 | β |
| Spot Urine Oxalate Testing in a Controlled Trial of Forced Hydration and Spinach Consumption. | Lemack B et al. | β | 2025 | β |
| 24-Hour Urinary Chemistries and Kidney Stone Risk. | Ferraro PM et al. | β | 2024 | β |
| Allopurinol hypersensitivity syndrome Raising awareness of an uncommon but potentially serious adverse event among kidney stone patients. | Alotaibi T et al. | β | 2024 | β |
| Chronic Fructose and Sucrose Intake and 24-Hour Urine Composition. | Prochaska M et al. | β | 2024 | β |
| Contrasting Response of Urine Stone Risk to Medical Treatment in Calcium Oxalate versus Calcium Phosphate Stone Formers. | Steely A et al. | β | 2024 | β |
| Effects of thiazides and new findings on kidney stones and dysglycemic side effects. | Bargagli M et al. | β | 2024 | β |
| Insulin Resistance in Hypercalciuric Calcium Kidney Stone Patients. | Prochaska M et al. | β | 2024 | β |
| Low daily water intake profile-is it a contributor to disease? | Armstrong LE et al. | β | 2024 | β |
| Management of <i>de novo</i> nephrolithiasis after kidney transplantation: a comprehensive review from the European Renal Association CKD-MBD working group. | Kanbay M et al. | β | 2024 | β |
| Prediction of 24-Hour Urinary Sodium Excretion Using Machine-Learning Algorithms. | Hamaya R et al. | β | 2024 | β |
| Primary hyperparathyroidism in adults-(Part I) assessment and medical management: Position statement of the endocrine society of Australia, the Australian & New Zealand endocrine surgeons, and the Australian & New Zealand bone and mineral society. | Milat F et al. | β | 2024 | β |
| The Plasma Metabolome and Risk of Incident Kidney Stones. | Ferraro PM et al. | β | 2024 | β |
| The Role of Urate in Calcium Stone Formation. | Critell E et al. | β | 2024 | β |
| Thiazides for kidney stone recurrence prevention. | Bargagli M et al. | β | 2024 | β |
| Unraveling the hidden link: neuroticism as a risk factor for upper urinary tract calculi-insights from Mendelian randomization analysis. | Gao S et al. | β | 2024 | β |
| Breaking the Cycle of Recurrent Calcium Stone Disease. | Malieckal DA et al. | β | 2023 | β |
| Epidemiology of Kidney Stones. | Stamatelou K et al. | β | 2023 | β |
| Lifestyle factors, serum parameters, metabolic comorbidities, and the risk of kidney stones: a Mendelian randomization study. | Liu M et al. | β | 2023 | β |
| Oxalate as a potent promoter of kidney stone formation. | Chen T et al. | β | 2023 | β |
| Phenome-wide association study of genetically predicted B vitamins and homocysteine biomarkers with multiple health and disease outcomes: analysis of the UK Biobank. | Wang L et al. | β | 2023 | β |
| Risk Factors for Common Kidney Stones Are Correlated with Kidney Function Independent of Stone Composition. | Simmons KE et al. | β | 2023 | β |
| Routine Urinary Biochemistry Does Not Accurately Predict Stone Type Nor Recurrence in Kidney Stone Formers: A Multicentre, Multimodel, Externally Validated Machine-Learning Study. | Geraghty RM et al. | β | 2023 | β |
| Sel1-like proteins and peptides are the major <i>Oxalobacter formigenes</i>-derived factors stimulating oxalate transport by human intestinal epithelial cells. | Arvans D et al. | β | 2023 | β |
| The effectiveness of citrates and pyridoxine in the treatment of kidney stones. | Ene MA et al. | β | 2023 | β |
| The Optimal Length of Pharmacological Prophylaxis in Calcium Kidney Stone Formers. | Lombardi G et al. | β | 2023 | β |
| Thiazide Use for the Prevention of Recurrent Calcium Kidney Stones. | Curhan GC et al. | β | 2023 | β |
| Urinary Metabolite Profile Predicting the Progression of CKD. | Kim Y et al. | β | 2023 | β |
| 24-hour sodium and potassium excretion in the Americas: a systematic review and meta-analysis. | Valero-Morales I et al. | β | 2022 | β |
| [Diagnostic values of urinary citrate for kidney stones in patients with primary gout]. | Wang Y et al. | β | 2022 | β |
| Dominant negative mutation in oxalate transporter <i>SLC26A6</i> associated with enteric hyperoxaluria and nephrolithiasis. | CorniΓ¨re N et al. | β | 2022 | β |
| Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. | Bilezikian JP et al. | β | 2022 | β |
| Neglected analytes in the 24-h urine: ammonium and sulfate. | Asplin JR | β | 2022 | β |
| Nuclear Magnetic Resonance Metabolomic Profiling and Urine Chemistries in Incident Kidney Stone Formers Compared with Controls. | Thongprayoon C et al. | β | 2022 | β |
| Role of insulin resistance and the gut microbiome on urine oxalate excretion in ob/ob mice. | Xiang H et al. | β | 2022 | β |
| UPDATE - Canadian Urological Association guideline: Evaluation and medical management of kidney stones. | Bhojani N et al. | β | 2022 | β |
| Update on Uric Acid and the Kidney. | Ramos GK et al. | β | 2022 | β |
| Association between hypomagnesemia and severity of primary hyperparathyroidism: a retrospective study. | Na D et al. | β | 2021 | β |
| Association of urate-lowering drugs with the risk of future urolithiasis in patients with gout: A population-based nested case-control study. | Wu SW et al. | β | 2021 | β |
| Comparison of Supersaturation Outputs from Different Programs and Their Application in Testing Correspondence with Kidney Stone Composition. | Rodriguez A et al. | β | 2021 | β |
| Effect of alanine supplementation on oxalate synthesis. | Wood KD et al. | β | 2021 | β |
| Evidence for abnormal linkage between urine oxalate and citrate excretion in human kidney stone formers. | Prochaska ML et al. | β | 2021 | β |
| Gut-kidney axis in oxalate homeostasis. | Alshaikh AE et al. | β | 2021 | β |
| Human kidney stones: a natural record of universal biomineralization. | Sivaguru M et al. | β | 2021 | β |
| Hydration for health hypothesis: a narrative review of supporting evidence. | Perrier ET et al. | β | 2021 | β |
| Incidence and Characteristics of Kidney Stones in Patients on Ketogenic Diet: A Systematic Review and Meta-Analysis. | Acharya P et al. | β | 2021 | β |
| Is It Time to Retire the Low-Oxalate Diet? No! | Crivelli JJ et al. | β | 2021 | β |
| Label-Free Protein Detection by Micro-Acoustic Biosensor Coupled with Electrical Field Sorting. Theoretical Study in Urine Models. | Mukhin N et al. | β | 2021 | β |
| Pathophysiology and Treatment of Enteric Hyperoxaluria. | Witting C et al. | β | 2021 | β |
| Pharmacological interventions for preventing complications in patients with idiopathic hypercalciuria: A systematic review. | Ferre N et al. | β | 2021 | β |
| Secondary Oxalate Nephropathy: Causes and Clinicopathological Characteristics of a Case Series. | Liang S et al. | β | 2021 | β |
| Sex Differences of Kidney Stone Urine Risk Factors after Roux-en-Y Gastric Bypass. | Prochaska M et al. | β | 2021 | β |
| Subsequent urinary stone events are predicted by the magnitude of urinary oxalate excretion in enteric hyperoxaluria. | D'Costa MR et al. | β | 2021 | β |
| Trends in the prevalence of kidney stones in the United States from 2007 to 2016. | Chewcharat A et al. | β | 2021 | β |
| Urine and stone analysis for the investigation of the renal stone former: a consensus conference. | Williams JC et al. | β | 2021 | β |
| Urine Uric Acid Excretion Levels are Positively Associated with Obesity and Abdominal Obesity in Type 2 Diabetes Patients without Chronic Kidney Disease. | Liu F et al. | β | 2021 | β |
| Activation of the PKA signaling pathway stimulates oxalate transport by human intestinal Caco2-BBE cells. | Arvans D et al. | β | 2020 | β |
| A Prospective, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Using an Orally Administered Oxalate Decarboxylase (OxDC). | Quintero E et al. | β | 2020 | β |
| Dietary Oxalate Intake and Kidney Outcomes. | Bargagli M et al. | β | 2020 | β |
| Disentangling the Relationships Between the Renin-Angiotensin-Aldosterone System, Calcium Physiology, and Risk for Kidney Stones. | Bayomy O et al. | β | 2020 | β |
| End Points for Clinical Trials in Primary Hyperoxaluria. | Milliner DS et al. | β | 2020 | β |
| Evidence for disordered acid-base handling in calcium stone-forming patients. | Worcester EM et al. | β | 2020 | β |
| Hypercalciuria: its value as a predictive risk factor for nephrolithiasis in asymptomatic primary hyperparathyroidism? | Saponaro F et al. | β | 2020 | β |
| Low urine pH predicts new onset of diabetes mellitus during a 10-year period in men: BOREAS-DM1 study. | Higashiura Y et al. | β | 2020 | β |
| Parathyroidectomy improves hypercalciuria in patients with primary hyperparathyroidism. | Shariq OA et al. | β | 2020 | β |
| Risk Factors for Kidney Stone Formation following Bariatric Surgery. | Prochaska M et al. | β | 2020 | β |
| The pelvis urinary microbiome in patients with kidney stones and clinical associations. | Liu F et al. | β | 2020 | β |
| Uric Acid and Urate in Urolithiasis: The Innocent Bystander, Instigator, and Perpetrator. | Adomako E et al. | β | 2020 | β |
| Dietary oxalate and kidney stone formation. | Mitchell T et al. | β | 2019 | β |
| Enhanced gastrointestinal passive paracellular permeability contributes to the obesity-associated hyperoxaluria. | Bashir M et al. | β | 2019 | β |
| Genome-wide Association Study of 24-Hour Urinary Excretion of Calcium, Magnesium, and Uric Acid. | Ware EB et al. | β | 2019 | β |
| Twenty-Four Hour Urine Testing and Prescriptions for Urinary Stone Disease-Related Medications in Veterans. | Song S et al. | β | 2019 | β |
| Adenosinergic signaling inhibits oxalate transport by human intestinal Caco2-BBE cells through the A<sub>2B</sub> adenosine receptor. | Jung D et al. | β | 2018 | β |
| Determinants of calcium and oxalate excretion in subjects with calcium nephrolithiasis: the role of metabolic syndrome traits. | Ticinesi A et al. | β | 2018 | β |
| Differences in renal ammonia metabolism in male and female kidney. | Harris AN et al. | β | 2018 | β |
| Efficacy and safety of alfacalcidol in Chinese postmenopausal women aged over 65 with osteoporosis or osteopenia: An open label, non-comparative, post marketing observational study. | Li N et al. | β | 2018 | β |
| Hyperuricosuric calcium urolithiasis. | Moe OW et al. | β | 2018 | β |
| Mechanism for higher urine pH in normal women compared with men. | Worcester EM et al. | β | 2018 | β |
| Menopause and Risk of Kidney Stones. | Prochaska M et al. | β | 2018 | β |
| Reduced active transcellular intestinal oxalate secretion contributes to the pathogenesis of obesity-associated hyperoxaluria. | Amin R et al. | β | 2018 | β |
| Relative Supersaturation of 24-Hour Urine and Likelihood of Kidney Stones. | Prochaska M et al. | β | 2018 | β |
| Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study. | Yu H et al. | β | 2018 | β |
| Short-Term Changes in Urinary Relative Supersaturation Predict Recurrence of Kidney Stones: A Tool to Guide Preventive Measures in Urolithiasis. | Ferraro PM et al. | β | 2018 | β |
| Vitamin B6 intake and the risk of incident kidney stones. | Ferraro PM et al. | β | 2018 | β |
| Adherence to the Mediterranean Dietary Pattern and Incidence of Nephrolithiasis in the Seguimiento Universidad de Navarra Follow-up (SUN) Cohort. | Leone A et al. | β | 2017 | β |
| Changes in urinary risk profile after short-term low sodium and low calcium diet in recurrent Swiss kidney stone formers. | Seeger H et al. | β | 2017 | β |
| Development of Nephrolithiasis in Asymptomatic Hyperuricemia: A Cohort Study. | Kim S et al. | β | 2017 | β |
| Effectiveness of Treatment Modalities on Kidney Stone Recurrence. | Zisman AL | β | 2017 | β |
| Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study. | Landgren AJ et al. | β | 2017 | β |
| <i>Oxalobacter formigenes-</i>Derived Bioactive Factors Stimulate Oxalate Transport by Intestinal Epithelial Cells. | Arvans D et al. | β | 2017 | β |
| Low Bone Density and Bisphosphonate Use and the Risk of Kidney Stones. | Prochaska M et al. | β | 2017 | β |
| Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease. | Solomon LR et al. | β | 2017 | β |
| Polymorphisms in Renal Ammonia Metabolism Genes Correlate With 24-Hour Urine pH. | Canales BK et al. | β | 2017 | β |
| Reproducibility of urinary biomarkers in multiple 24-h urine samples. | Sun Q et al. | β | 2017 | β |
| Serum Uric Acid and Risk of Kidney Stones. | Ferraro PM et al. | β | 2017 | β |
| Should metabolic evaluation be performed in patients with struvite stones? | Iqbal MW et al. | β | 2017 | β |
| Urinary Calcium Excretion and Risk ofΒ Chronic Kidney Disease in the GeneralΒ Population. | Taylor JM et al. | β | 2017 | β |
| Vitamin D deficiency is prevalent among idiopathic stone formers, but does correction pose any risk? | Johri N et al. | β | 2017 | β |
| Vitamin D Intake and the Risk of Incident Kidney Stones. | Ferraro PM et al. | β | 2017 | β |
| CUA guideline on the evaluation and medical management of the kidney stone patient - 2016 update. | Dion M et al. | β | 2016 | β |
| Effects of non-pharmacological interventions on urinary citrate levels: a systematic review and meta-analysis. | Pachaly MA et al. | β | 2016 | β |
| Idiopathic hypercalciuria and formation of calcium renal stones. | Coe FL et al. | β | 2016 | β |
| Insights Into Nephrolithiasis From the Nurses' Health Studies. | Prochaska ML et al. | β | 2016 | β |
| Lowering urinary oxalate excretion to decrease calcium oxalate stone disease. | Holmes RP et al. | β | 2016 | β |
| Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. | Gambaro G et al. | β | 2016 | β |
| Nephrolithiasis and Risk of Incident Bone Fracture. | Taylor EN et al. | β | 2016 | β |
| Oxalate Concentrations in Human Gastrointestinal Fluid. | Reddy TG et al. | β | 2016 | β |
| Treatment of patients with uric acid stones. | Heilberg IP | β | 2016 | β |
| Associations of dietary macronutrients with glomerular filtration rate and kidney dysfunction: Tehran lipid and glucose study. | Yuzbashian E et al. | β | 2015 | β |
| Biochemical diagnosis in 3040 kidney stone formers in Argentina. | Spivacow FR et al. | β | 2015 | β |
| Clinical and metabolic evaluation of patients with history of renal calculi in Qazvin, Iran. | Charkhchian M et al. | β | 2015 | β |
| [Diagnosis and treatment of nephrolithiasis. What is established?]. | Pfau A et al. | β | 2015 | β |
| Explicit Modeling of Ancestry Improves Polygenic Risk Scores and BLUP Prediction. | Chen CY et al. | β | 2015 | β |
| Hyperoxaluria and Genitourinary Disorders in Children Ingesting Almond Milk Products. | Ellis D et al. | β | 2015 | β |
| Nutritional Management of Kidney Stones (Nephrolithiasis). | Han H et al. | β | 2015 | β |
| Optimal criteria for microscopic review of urinalysis following use of automated urine analyzer. | Khejonnit V et al. | β | 2015 | β |
| Caffeine intake and the risk of kidney stones. | Ferraro PM et al. | β | 2014 | β |
| Characterisation of risk factors for stones in hyperuricosuric men attending a stone clinic. | Walker V et al. | β | 2014 | β |
| Fish oil supplementation and urinary oxalate excretion in normal subjects on a low-oxalate diet. | Lange JN et al. | β | 2014 | β |
| Medical and dietary therapy for kidney stone prevention. | Gul Z et al. | β | 2014 | β |
| Role of sodium restriction in recurrent stone formers with hyperoxaluria. | Garg N et al. | β | 2014 | β |
| The crystallization of monosodium urate. | Martillo MA et al. | β | 2014 | β |
| Treatment of calcium nephrolithiasis in the patient with hyperuricosuria. | Arowojolu O et al. | β | 2014 | β |
| Dietary and lifestyle factors and medical conditions associated with urinary citrate excretion. | Mandel EI et al. | β | 2013 | β |
| Effect of adiponectin on kidney crystal formation in metabolic syndrome model mice via inhibition of inflammation and apoptosis. | Fujii Y et al. | β | 2013 | β |
| Frequency of rare allelic variation in candidate genes among individuals with low and high urinary calcium excretion. | Toka HR et al. | β | 2013 | β |
| Hydrochlorothiazide compared to chlorthalidone in reduction of urinary calcium in patients with kidney stones. | Wolfgram DF et al. | β | 2013 | β |
| Internet program for facilitating dietary modifications limiting kidney stone risk. | Lange JN et al. | β | 2013 | β |
| Novel locus including FGF21 is associated with dietary macronutrient intake. | Chu AY et al. | β | 2013 | β |
| Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones. | Goldfarb DS et al. | β | 2013 | β |
| Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. | Sakhaee K et al. | β | 2012 | β |
| Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. | Gallagher JC et al. | β | 2012 | β |
| Sensitivity of human strains of Oxalobacter formigenes to commonly prescribed antibiotics. | Lange JN et al. | β | 2012 | β |
| The association of cardiovascular disease and metabolic syndrome with nephrolithiasis. | Lange JN et al. | β | 2012 | β |
| Uric acid stones and hyperuricosuria. | Mehta TH et al. | β | 2012 | β |
| Fluid intake for kidney disease prevention: an urban myth? | Chang A et al. | β | 2011 | β |
| Genome-wide association study identifies a locus at 7p15.2 associated with endometriosis. | Painter JN et al. | β | 2011 | β |
| Impact of dietary calcium and oxalate, and Oxalobacter formigenes colonization on urinary oxalate excretion. | Jiang J et al. | β | 2011 | β |
| Laterality of nephrocalcinosis in kidney stone formers with severe hypocitraturia. | Le JD et al. | β | 2011 | β |
| Metabolism of primed, constant infusions of [1,2-ΒΉΒ³Cβ] glycine and [1-ΒΉΒ³Cβ] phenylalanine to urinary oxalate. | Knight J et al. | β | 2011 | β |
| Oxalate and sucralose absorption in idiopathic calcium oxalate stone formers. | Knight J et al. | β | 2011 | β |
| Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria. | Goldfarb DS | β | 2011 | β |
| Uric Acid Nephrolithiasis: A Systemic Metabolic Disorder. | Wiederkehr MR et al. | β | 2011 | β |
| Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements. | Wallace RB et al. | β | 2011 | β |
| Urolithiasis through the ages: data on more than 200,000 urinary stone analyses. | Knoll T et al. | β | 2011 | β |
| Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia. | Beara-Lasic L et al. | β | 2010 | β |
| DASH-style diet and 24-hour urine composition. | Taylor EN et al. | β | 2010 | β |
| Evaluation and medical management of the kidney stone patient. | Paterson R et al. | β | 2010 | β |
| Metabolism of fructose to oxalate and glycolate. | Knight J et al. | β | 2010 | β |
| Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. | Saccone NL et al. | β | 2010 | β |
| DASH-style diet associates with reduced risk for kidney stones. | Taylor EN et al. | β | 2009 | β |
| Demographic, dietary, and urinary factors and 24-h urinary calcium excretion. | Taylor EN et al. | β | 2009 | β |
| Effects of Lactobacillus casei and Bifidobacterium breve on urinary oxalate excretion in nephrolithiasis patients. | Ferraz RR et al. | β | 2009 | β |
| Hypocitraturia: pathophysiology and medical management. | Zuckerman JM et al. | β | 2009 | β |
| Update on the medical management of stone disease. | Tracy CR et al. | β | 2009 | β |
| Use of the frc gene as a molecular marker to characterize oxalate-oxidizing bacterial abundance and diversity structure in soil. | Khammar N et al. | β | 2009 | β |
| Determinants of 24-hour urinary oxalate excretion. | Taylor EN et al. | β | 2008 | β |
| Phenotypic and functional analysis of human SLC26A6 variants in patients with familial hyperoxaluria and calcium oxalate nephrolithiasis. | Monico CG et al. | β | 2008 | β |